Much progress has been made in research and development of new drugs for TB over the last decade. There are currently eight new or repurposed drugs in Phase I, Phase II or Phase III trials for the treatment of drug-susceptible, drug-resistant TB or latent TB infection.
- Much progress has been made in research and development of new drugs for TB over the last decade.
- There are currently eight new or repurposed drugs in Phase I, Phase II or Phase III trials for the treatment of drug-susceptible, drug-resistant TB or latent TB infection.
- Two novel drugs, bedaquiline and delamanid, have been approved by stringent regulatory authorities under accelerated or conditional approval procedures for the treatment of MDR-TB as part of combination therapy for adults with pulmonary TB when other alternatives are not available.